At 10.5% CAGR, the Asia Pacific Newborn Screening Market is Projected to be Worth US$ 602.14 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Asia Pacific newborn screening market was valued at US$ 270.13 in 2022 and is expected to reach US$ 602.14 million by 2030, registering a CAGR of 10.5% from 2022 to 2030. Genetic screening of newborns and rising burden of congenital diseases are among the critical factors attributed to the Asia Pacific newborn screening market expansion.

Congenital diseases can lead to lifelong health challenges if not detected and managed early. These diseases can contribute to long-term disability, significantly affecting families, individuals, healthcare systems, and societies. The WHO estimates that 240,000 newborns worldwide succumb to death each year within 28 days of birth due to these diseases. An additional 170,000 children die between the age of 1 month and 5 years due to congenital diseases. A growing understanding of the genetic basis of many congenital diseases is one of the several factors contributing to the increasing burden of these conditions. Advancements in genomics and genetic testing have enabled healthcare providers to identify a broader range of genetic mutations and conditions in newborns. This expanded knowledge has highlighted the importance of early diagnosis through newborn screening to initiate timely interventions and treatments.

Changing demographics such as maternal age, environmental exposures, and altering lifestyle habits increase the risk of congenital conditions in newborns. Moreover, the number of births occurring every day is on the rise due to the burgeoning global population, resulting in an expanding pool of infants that can be at risk of congenital diseases. In addition, healthcare systems and policymakers recognize the long-term benefits of early disease detection. They increasingly incorporate newborn screening into routine healthcare protocols and insurance coverage, further stimulating market growth. The rising burden of congenital diseases is a significant driver behind the growth of the newborn screening market.

On the contrary, lack of uniformity in newborn screening policies and practices hampers the growth Asia Pacific newborn screening market.

Based on product type, the Asia Pacific newborn screening market is bifurcated into reagents and assay kits, and instruments. The reagents and assay kits segment held 73.9% share of the Asia Pacific newborn screening market in 2022, amassing US$ 199.56 million. It is projected to garner US$ 473.69 million by 2030 to expand at 11.4% CAGR during 2022-2030. The reagents and assay kits segment is subsegmented into DNA-based assays, and immunoassays and enzymatic assays. Instruments segment is subsegmented into newborn disorder screening instruments, pulse oximeters, newborn hearing screening instruments, and other instruments.

In terms of technology, the Asia Pacific newborn screening market is categorized into tandem mass spectrometry (TMS), molecular assays, immunoassays and enzymatic assay, pulse oximetry screening technology, and other technologies. The pulse oximetry screening technology segment held 32.3% share of the Asia Pacific newborn screening market in 2022, amassing US$ 87.22 million. It is projected to garner US$ 200.41 million by 2030 to expand at 11.0% CAGR during 2022-2030.

Based on test type, the Asia Pacific newborn screening market is categorized into dry blood spot test, hearing screen test, critical congenital heart diseases (CCHD) test, and other test types. The dry blood spot test segment held 53.7% share of Asia Pacific newborn screening market in 2022, amassing US$ 145.01 million. It is projected to garner US$ 339.70 million by 2030 to expand at 11.2% CAGR during 2022-2030.

By end user, the Asia Pacific newborn screening market is segmented into hospitals and clinics and diagnostic laboratories. The hospitals and clinics segment held 64.8% share of Asia Pacific newborn screening market in 2022, amassing US$ 412.72 million. It is projected to garner US$ 174.92 million by 2030 to expand at 11.3% CAGR during 2022-2030.

Based on country, the Asia Pacific newborn screening market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held 24.9% share of Asia Pacific newborn screening market in 2022, amassing US$ 67.37 million. It is projected to garner US$ 165.18 million by 2030 to expand at 11.9% CAGR during 2022-2030.

Key players operating in the Asia Pacific newborn screening market are Bio-Rad Laboratories Inc, LifeCell International Pvt Ltd, Masimo Corp, Medtronic Plc, Natus Medical Inc, PerkinElmer Inc, Trivitron Healthcare Pvt Ltd, and Waters Corp, among others.

- In May 2023, Masimo launched Stork, a revolutionary home baby monitoring system. This innovative system offers parents insights into their baby's health data, helping them learn more about and connect better with their baby. The Masimo Stork baby monitor system comprises several components and is available in multiple configurations. Masimo Stork Vitals+, the flagship solution, consists of a boot with a sensor, video camera, and mobile app.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com